Clinical trial · Observational
Gefitinib Usage and Outcomes in Routine Treatment
A Multicentre, Retrospective Chart Review Study to Characterise Gefitinib Usage and Outcomes in Routine Treatment
NCT01818947CI-TRIAL-00013538completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to understand real world gefitinib usage patterns, patient characteristics and outcomes and to present these for a Caucasian population
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Gefitinib
Primary outcomes (2)
- measure
- Assessment of treatment duration, as a surrogate of Clinical Benefit (CB) in a 'Real World' population treated with gefitinib
- timeFrame
- 6 months
- description
- Retrospective population \[2009 to 2013\]
- measure
- Assessment of Overall Survival (OS) in a 'Real World' population treated with gefitinib
- timeFrame
- 6 months
- description
- Retrospective population \[2009 to 2013\]
Secondary outcomes (6)
- measure
- Assessment of Overall Survival (OS) in the subgroup of patients of Caucasian ethnicity and in the subgroup of patients treated with gefitinib for at least 3 months
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who received gefitinib first line in the UK Single Payment Access (SPA) scheme * Locally advanced or metastatic EGFR mutation positive NSCLC * Supplied with first pack of gefitinib prior to 1st January 2012 Exclusion Criteria: * Patient was treated privately (i.e. outside the NHS) * Gefitinib was second-line therapy following treatment failure on a prior therapy
References
Publications (0)
Data not yet available
No reference posted for this study.